SCHEMBL7235339

SCHEMBL7235339

O=[C]N1CCN(C(=O)c2ccnc(Cl)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PROKR1 Q8TCW9 1/20 0.51
GFER P55789 1/20 0.46
KDM4E B2RXH2 1/20 0.46
PKM P14618 2/20 0.45
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
STAT3 P40763 1/20 0.42
KMT2A Q03164 1/20 0.42
LMNA P02545 1/20 0.42
HSD17B10 Q99714 1/20 0.42
AKR1C3 P42330 1/20 0.41
SLC6A7 Q99884 1/20 0.41
TP53 P04637 1/20 0.41
SMYD3 Q9H7B4 1/20 0.40
RAB9A P51151 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6179175 0.84 PROKR1 (0.53) PROKR1GFERKDM4EPKMALDH1A1
SCHEMBL937205 0.84 PROKR1 (0.63) PROKR1GFERKDM4EPKMALDH1A1
SCHEMBL939096 0.84 PROKR1 (0.63) PROKR1GFERKDM4EALDH1A1HPGD
SCHEMBL4059188 0.83 POLB (0.59) PROKR1GFERKDM4EALDH1A1HPGD
SCHEMBL30667713 0.83 PROKR1 (0.61) PROKR1GFERALDH1A1HPGDMEN1
SCHEMBL1859158 0.83 PROKR1 (0.61) PROKR1GFERALDH1A1HPGDMEN1
SCHEMBL3763863 0.81 PROKR1 (0.50) PROKR1GFERKDM4EPKMALDH1A1
SCHEMBL3249195 0.80 PKM (0.63) PROKR1KDM4EPKMALDH1A1HPGD
SCHEMBL7492026 0.80 SIGMAR1 (0.54) PROKR1GFERKDM4EHPGD
SCHEMBL7496576 0.79 SMN1; SMN2 (0.49) PROKR1GFERKDM4EPKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586423-B2 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy MERCK & CO., INC. 2003-07-01 US disclosed